Eddie Moradian, President of MD Biosciences states, "At MD Biosciences, we have always promised our clients that we will meet their needs now and in the future; our expansion ensures that commitment. We doubled our lab space so that we are able to provide 150 percent more services and increase product development by 130 percent in the coming year in comparison with the last.
Our relocation is just one step of many in the endeavor to continue to offer the highest quality services and products in assisting our customers in meeting their objectives. Future projections include adding more highly specialized scientists to our team and increasing our focus on our available products and proprietary reagents."
About MD Biosciences
MD Biosciences provides products and pre-clinical services, which include efficacy testing, mode of action platforms, in vitro analysis, histology and imaging for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of experts to tackle problems and provide solutions. MDB also supplies for purchase by all laboratories many of the products and proprietary reagents used in our research, regardless of whether MDB is contracted as a research organization. This allows our clients to optimize their own research process by selecting steps to be performed by MDB and research to be performed in-house.
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.